Cannabidiol significantly reduces seizures in Lennox-Gastaut syndrome

cannabidiol-vial

In a new study published in The New England Journal of Medicine the researchers, comparing two doses of Cannabidiol (CBD) to a placebo, reported a 41.9 percent reduction in "drop seizures" in patients taking a 20 mg/kg/d Cannabidiol (CBD) regimen, a 37.2 percent reduction in those on a 10 mg/kg/d Cannabidiol (CBD) regimen, and a 17.2 percent reduction in a group given a placebo. The phase III trial was led by principal investigator and study first co-author Orrin Devinsky, MD, a professor of neurology, neurosurgery, and psychiatry at NYU School of Medicine and director of NYU Langone's Comprehensive Epilepsy Center. The study...
Continue reading
  967 Hits
967 Hits

Cannabidiol effective in treatment of intractable epilepsy

Cannabidiol effective in treatment of intractable epilepsy
Results from open-label Expanded Access treatment programs from 16 centres presented at the 2015 American Epilepsy Society Annual Meeting in Philadelphia, show that Epidiolex, a pharmaceutical-grade, purified form of cannabidiol, is generally well-tolerated and is a promising treatment for treatment-resistant epilepsies. Epidiolex, manufactured by GW Pharma, is a highly-standardized, plant-derived form of cannabidiol (CBD), the most abundant non-psychoactive cannabinoid derived from the cannabis plant. Anecdotal reports and animal studies in multiple species and models have shown anticonvulsant efficacy for cannabidiol in intractable epilepsies including Dravet syndrome and Lennox-Gastaut syndrome. For the current study by Devinsky et al, children and young...
Continue reading
  2990 Hits
2990 Hits
Select Language

ICNApedia Community Pages

Journal of the International Child Neurology Association

icnapedia vle

ICNC2018 Mumbai India